Follistatin-344

Other Research Peptides

aka FS344 · FST344 · Human follistatin-344 precursor

Compare

Formula

—

MW (Da)

Half-life

hours (recombinant protein, route-dependent)

Saves

Overview

Follistatin-344 is the 344-amino-acid precursor form of follistatin, a secreted glycoprotein. In human translational work it is most often encountered as an AAV-delivered transgene (AAV1.CMV.huFollistatin344), not as an injectable peptide — a distinction that materially affects how mechanism, dosing, and safety should be interpreted.

Mechanism

Human follistatin cDNA encodes a 344-aa protein with a 29-aa signal sequence, an atypical N-terminal TGF-binding domain, three follistatin domains, and an acidic C-terminal tail. Functionally, follistatin binds and neutralizes activin A, myostatin, and related TGF-β family ligands, reducing downstream SMAD2/3 signaling and relieving inhibition of skeletal-muscle growth. This is a well-established biologic mechanism, but the clinical context is gene transfer rather than direct protein injection.

0

Vendors

—

no vendors yet

Lowest price

—

Reported benefits

Encouraging early signals in Becker muscular dystrophy gene-therapy trial

A phase 1/2a trial used follistatin gene transfer as a myostatin-pathway antagonist in Becker muscular dystrophy; study authors described the results as encouraging, including ambulation signals.

[follistatin-bmd-pmc]

clinical

Mechanism applicable to dystrophin-deficient muscle disorders

Related reviews discuss broader translational rationale for myostatin-pathway antagonism in dystrophin-deficient muscle disorders.

[follistatin-pubmed-myostatin]

clinical

Reported side effects

Safety not directly transferable from gene-therapy context
anecdotal
The clinical modality is AAV gene transfer, not standard peptide dosing. Adverse-event interpretation depends on viral vector exposure, which does not apply to peptide or recombinant-protein self-administration.
No direct-protein human adverse-event dataset retrieved
anecdotal
Accessible study summaries and trial registry entries do not provide a clean direct-protein adverse-event incidence table; side effects must be considered delivery-context specific.

Dosing notes

Direct peptide dosing is unspecified in the retrieved human literature because the clinical evidence centers on AAV gene transfer, not peptide or recombinant follistatin injection. Recombinant laboratory reagents typically represent aa 30–344 protein products for research use only, not for human administration.

Research use only. Information on this page is editorial reference, not medical or dosing advice. Always consult qualified medical guidance before use.

Storage

For recombinant human follistatin protein products, Bio-Techne states that lyophilized protein ships at ambient temperature but should then be stored under freezer conditions, avoiding repeated freeze-thaw cycles; reconstitution guidance includes 100 μg/mL in sterile PBS with carrier protein recommended. Novus lists 12 months at -20 to -70 °C as supplied, and about 1 month at 2–8 °C after reconstitution. Vendor values for recombinant protein formats only — not for gene-therapy vectors.

Vendors carrying Follistatin-344

No approved vendors are listing this peptide yet. Check back later or browse the full vendor directory.

Discussion

Ask, answer, and vote on questions about Follistatin-344.

No questions yet. Be the first to ask.

References

[follistatin-biotechne]
Recombinant human follistatin aa 30–344 protein datasheet
R&D Systems / Bio-Techne · R&D Systems datasheet
Source
[follistatin-biotechne-product]
Recombinant human follistatin aa 30–344 protein product page
Bio-Techne · Bio-Techne product page
Source
[follistatin-bmd-pmc]
Follistatin gene transfer in Becker muscular dystrophy (phase 1/2a)
Mendell JR et al. · PubMed Central
Source
[follistatin-pubmed-myostatin]
Follistatin and myostatin-pathway antagonism in muscular dystrophy
Authors per PubMed entry · PubMed
Source
[follistatin-trial-nct]
NCT01519349: AAV1.CMV.huFollistatin344 gene transfer trial
ClinicalTrials.gov record · ClinicalTrials.gov
Source